- Home
- USIO vs CALC Comparison
USIO vs CALC Comparison
Compare USIO & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- CALC
- Stock Information
- Founded
- USIO 1998
- CALC 2011
- Country
- USIO United States
- CALC United States
- Employees
- USIO N/A
- CALC N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- CALC Health Care
- Exchange
- USIO Nasdaq
- CALC Nasdaq
- Market Cap
- USIO 41.5M
- CALC 36.0M
- IPO Year
- USIO N/A
- CALC N/A
- Fundamental
- Price
- USIO $1.42
- CALC $1.97
- Analyst Decision
- USIO Strong Buy
- CALC Strong Buy
- Analyst Count
- USIO 2
- CALC 4
- Target Price
- USIO $5.00
- CALC $17.25
- AVG Volume (30 Days)
- USIO 118.4K
- CALC 32.6K
- Earning Date
- USIO 03-26-2025
- CALC 03-27-2025
- Dividend Yield
- USIO N/A
- CALC N/A
- EPS Growth
- USIO N/A
- CALC N/A
- EPS
- USIO 0.13
- CALC N/A
- Revenue
- USIO $81,027,258.00
- CALC N/A
- Revenue This Year
- USIO $2.58
- CALC N/A
- Revenue Next Year
- USIO $13.40
- CALC N/A
- P/E Ratio
- USIO $10.71
- CALC N/A
- Revenue Growth
- USIO N/A
- CALC N/A
- 52 Week Low
- USIO $1.24
- CALC $1.86
- 52 Week High
- USIO $2.92
- CALC $6.27
- Technical
- Relative Strength Index (RSI)
- USIO 36.10
- CALC 34.55
- Support Level
- USIO $1.37
- CALC $2.02
- Resistance Level
- USIO $1.57
- CALC $2.35
- Average True Range (ATR)
- USIO 0.10
- CALC 0.23
- MACD
- USIO -0.02
- CALC 0.00
- Stochastic Oscillator
- USIO 13.95
- CALC 26.35
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for the Output Solutions operations.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.